Genome-wide screenings identify BAP1 as a synthetic-lethality target with CDK4/6 inhibitors

1 min read

In a breakthrough study published in Science Advances, researchers led by Dr. Feng have uncovered an epigenetic pathway driving adaptive resistance to cyclin-dependent kinase 4/6 (CDK4/6) inhibitors in hepatobiliary cancers. By combining genome-wide CRISPR screenings with comprehensive transcriptional, epigenetic, and proteomic profiling, the team identified BAP1 as a critical regulator of tumor plasticity and adaptive resistance.

The discovery was made possible by sustained CDK4/6 inhibition, which triggers BAP1-dependent chromatin remodeling that induces a stem cell-like epigenetic state. Specifically, BAP1 removes ubiquitin modification at the TCF4 promoter, activating WNT and EMT signaling to enhance cellular plasticity and survival under therapy. This process allows cancer cells to adapt and become more resistant to treatment, highlighting the need for new strategies to overcome this resistance.

The team's findings also show that genetic and pharmacologic inhibition of BAP1 markedly improves abemaciclib efficacy in multiple mouse models and patient-derived organoids (PDOs). This suggests a promising approach for targeting quiescent, drug-resistant cancer cells. By understanding the molecular mechanisms underlying adaptive resistance, researchers can develop more effective treatments to overcome this challenge.

The discovery of BAP1's role in tumor plasticity and adaptive resistance has profound implications for our understanding of cancer biology. As we gaze up at the stars, we are reminded that even the most complex biological systems are governed by fundamental laws of physics and chemistry. The intricate dance of epigenetic regulators like BAP1 holds the key to unlocking new strategies for cancer treatment, and it is a testament to human ingenuity and curiosity that we continue to explore and understand the mysteries of our own bodies.

1 min read

For years, scientists have been searching for ways to keep cancer cells from escaping the brakes that slow down their growth. But so far, they've only scratched the surface of understanding how this works.

Researchers have now made a significant discovery about one key player in this process: BAP1. They found that when cancer cells try to evade the effects of a particular type of therapy - called CDK4/6 inhibitors - BAP1 becomes involved in a hidden pathway. This pathway is like a secret route that helps cancer cells survive and adapt.

By studying how BAP1 works, the scientists have uncovered an important clue about how to beat back this adaptive resistance. They've found that targeting BAP1 can make therapy more effective by stopping these secret routes from working. This could be a promising new way to combat a common challenge in cancer treatment: when cancer cells become resistant to therapy and start to come back stronger than before.

1 min read

In the darkest corners of our bodies, tiny changes can lead to big problems. Cancer cells, once held back by cell cycle inhibitors, find ways to escape and grow out of control. We don't fully understand how this happens.

But now, scientists have uncovered a key player in this game: BAP1. This protein helps cancer cells adapt by changing the way they read their genes. When BAP1 is blocked, cancer cells become more vulnerable to therapy, like a door that's suddenly unlocked. Researchers found that targeting BAP1 can even make treatments that were struggling work better.